期刊
ONCOTARGETS AND THERAPY
卷 12, 期 -, 页码 8595-8600出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S219512
关键词
LELC; NSCLC; nivolumab; PD-L1
资金
- National Science Foundation of China [81700095, 81870034]
Objectives: Lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer (NSCLC). No clinical trials have been performed, and no course of treatment for LELC has been established because of it's rarity. This study presents a patient with primary pulmonary LELC, who was treated with nivolumab, and responded favorably. Materials and methods: A patient with primary pulmonary LELC was treated using nivolumab. Result: The patient responded well to immunotherapy with nivolumab. After five cycles of the nivolumab, the size of the tumor and the lesions of the liver became smaller. A blood test showed that CYFRA21-1 and NSE had dramatically decreased from before, especially the CYFRA21-1. Conclusion: EBV-positive pulmonary LELC with high expression of PD-Ll may derive a benefit from PD-1/PD-L1 blockade.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据